Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8%.

Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance has led Novonesis to now expect full-year organic sales growth to be at the upper end of the 7-8% range, and the adjusted EBITDA margin is confirmed to be between 35.5-36.5%. 

The sales growth is driven by both Food & Health Biosolutions and Planetary Health Biosolutions. 

• Novonesis is in a very good place, and our strong execution across the business highlights the strength of our diversified portfolio, innovative capabilities, and broad-based market reach. says Ester Baiget, President and CEO.

Novonesis is the result of a merger between Novozymes and Chr. Hansen, completed on January 29, 2024. Reflecting on the merger and the quarterly results, Ester Baiget adds:

• Now, nine months after our combination was completed, we stand as one company with 10,000 colleagues around the globe, all coming to work to better our world with biology. I am profoundly grateful for the immense dedication and commitment across the company. This collective effort will enable us to reach our full potential and lead the era of biosolutions,

Read the full press release HERE

Photo: Ester Baiget, President and CEO, Novonesis